A Phase 1/2 Trial of Durvalumab (MEDI4736) When Given as a Single Agent or in Combination With Lenalidomide in Patients With Relapsed/ Refractory Peripheral T-cell Lymphoma, Including Cutaneous T-cell Lymphoma
Latest Information Update: 08 Aug 2024
At a glance
- Drugs Durvalumab (Primary) ; Lenalidomide
- Indications Cutaneous T-cell lymphoma; Mycosis fungoides; Peripheral T-cell lymphoma; Sezary syndrome
- Focus Adverse reactions; Therapeutic Use
- 06 Aug 2024 Status changed from recruiting to active, no longer recruiting.
- 12 Dec 2023 Preliminary Results (n=23 ) assessing safety and efficacy of Durvalumab (Anti-PD-L1) & Lenalidomide in Refractory/Advanced Cutaneous T Cell Lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Jan 2023 Planned End Date changed from 8 Jun 2023 to 1 Jun 2026.